Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats [PDF]
, 2015 core +1 more source
Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors. [PDF]
Eur J Med ResSaber K +4 more
europepmc +1 more source
CD26 as a potential therapeutic target for lung adenocarcinoma. [PDF]
Front OncolJungraithmayr W +10 more
europepmc +1 more source
Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis [PDF]
, 2013 core +1 more source
Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. [PDF]
CureusSelvaraj V.
europepmc +1 more source
Development and Validation of High-Performance Thin Layer Chromatographic Method for the Simultaneous Estimation of Dapagliflozin and Vildagliptin in Fixed-Dose Combination. [PDF]
Turk J Pharm SciKrishnamoorthy YV +2 more
europepmc +1 more source
Therapeutic impact of vildagliptin vs. gliclazide on insulin resistance and advanced glycated end product levels in newly diagnosed Egyptian diabetics: a randomized controlled trial. [PDF]
Eur J Clin PharmacolElemary T +3 more
europepmc +1 more source
Vildagliptin modulates the microbiota and induces an immunometabolic profile compatible with neuroprotection in type 2 diabetes. [PDF]
Sci Repde Macedo JCC +9 more
europepmc +1 more source